Fig A12.

Amplifications in MDM2 or MDM4 were found in eight patients. Each plot shows the copy number (CN) log ratio of the overall CN segmentations across chromosomes (Chr). Estimated integer CNs are reported for each patient and calculated by FACETS. One patient had durable clinical benefit and five of eight patients had > 2 months progression-free survival. The patient with the greatest amplification had rapid progression. The progression-free survival curve of patients with MDM2 or MDM4 amplifications are compared with those with MDM2/MDM4 wild type (hazard ratio, 1.4; P = .44).